Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. LMT
9. SPY
10. SBUX

Go back to Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 8c

Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 3, 2022 4:01 PM EDT

Q2 2022 total revenues were $64.4 millionTotal revenues in the first six months of 2022 were $124.6 millionVanda provides update on pipeline advancements and upcoming milestones

WASHINGTON, Aug. 3, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2022.

"During the second quarter we made significant progress towards commercializing our products and improving access to HETLIOZ® for patients with Non-24," said Mihael H.... More